Turinabol is an anabolic steroid that is close in positive and side effects as well as chemical structure to Methandienone. The difference from Methandienone is that Turinabol contains an additional chlorine atom at the fourth carbon atom. The drug was first developed by the German pharmaceutical company Jenapharm and patented in 1961.
The product can be described as Methandienone without the effect of fluid retention in the body.
It is a delayed acting steroid. During the Turinabol cycle, weight, strength and relief progress very slowly, but according to athletes these results are better.
Another distinctive feature of the drug is the absence of estrogenic effects (since it is not subjected to aromatization, due to the addition of a chlorine atom in the molecule), that is, side effects such as fluid accumulation, gynecomastia, etc. practically do not occur. Although there are reviews that report on the development of gynecomastia, the mechanism of development of which remains unclear. The most likely reason is the presence of Methyltestosterone in the composition, which is due to the peculiarities of synthesis.
Also, it was determined that the concentration of SHBG decreases, so the level of free testosterone in the blood increases. There is evidence that Turinabol reduces the risk of blood clots in the blood vessels and heart.
Turinabol Side Effects
Turinabol is a 17-alkylated anabolic steroid, which makes oral administration possible, but creates a toxic effect for the liver, comparable to Methandienone. In General, side effects are quite rare and are most often associated with exceeding the duration of the cycle and high doses. This steroid strongly inhibits the secretion of their own testosterone. Possible erectile dysfunction after cancellation, there were cases of premature ejaculation.
Cholestatic jaundice, necrosis of hepatocytes with liver failure, liver cancer. From the biochemical parameters is determined by increasing the level of bilirubin, alkaline phosphatase and transaminases. Cholestatic jaundice can develop after 6 months or more (is a toxic Genesis) and is manifested by stasis in bile capillaries with hyperbilirubinemia and increased activity of alkaline phosphatase. When used for several years may increase the frequency of liver cancer.
There was an official report on the carcinogenic effect of 5 years of use of Turinabol in relatively high doses.
Turinabol less often than other drugs in men can cause: inhibition of spermatogenesis and impotence (a second decrease in the secretion of gonadotropins and testosterone levels with testicular atrophy and oligospermia); prostatic hypertrophy (mainly in the elderly); epididymitis; priapism. Boys may experience premature puberty, frequent erections, the risk of stunting.
Excitement, confusion, insomnia and depression.
Reduction of glucose tolerance; increase in low density lipoprotein (LDL); the acceleration of the excretion of creatinine; increase in the content of creatine kinase; swelling relatively rarely observed due to a slight delay of sodium and water; a delay of potassium, calcium and phosphorus. Patients with long-term bed rest may develop hypercalcemia.
During puberty, epiphyseal zones of bones with growth retardation may close prematurely.
In women, the drug can rarely cause: reduced secretion of gonadotropins; virilization phenomena (acne, hirsutism, coarsening of the voice, increased libido, menstrual irregularities, hypertrophy of the clitoris, muscle development). Pregnant women may develop virilization of the female fetus. Frequency data of adverse effects from Turinabol low.